TickerFacts.

Company research / HALO

Halozyme Therapeutics, Inc. (HALO)

Build a valuation ↗↓ Download CSV

SEC name HALOZYME THERAPEUTICS, INC. · CIK 0001159036 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Halozyme Therapeutics, Inc. reported revenue of $1.40B. Revenue grew 37.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $1.66B.

Key ratios (year ended 2025-12-31)

83.6%
Gross margin (computed)
33.6%
Operating margin
22.7%
Net margin
649.2%
Return on year-end equity
37.6%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-08

Headquarters locality: San Diego · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$1.66B$1.40B$1.02B$829.25M$660.12M$443.31M$267.59M$195.99M$151.86M$316.61M$146.69M
Cost of Revenue$292.42M$228.77M$159.42M$192.36M$139.30M$81.41M$43.37M$45.55M$10.14M$31.15M$33.21M
Gross Profit (computed)$1.37B$1.17B$855.91M$636.89M$520.81M$361.90M$224.23M$150.45M$141.73M$285.46M$113.48M
R&D Expense$102.37M$81.49M$79.05M$76.36M$66.61M$35.67M$34.24M$140.80M$150.25M$150.64M$150.84M
Operating Income$597.20M$469.01M$551.48M$337.57M$267.53M$275.90M$144.25M-$67.61M-$69.33M$81.00M-$83.21M
Depreciation & Amortization$14.64M$11.39M$10.26M$11.08M$6.49M$3.00M$3.28M$4.07M$2.39M$2.16M$2.41M
EBITDA$611.84M$480.39M$561.74M$348.66M$274.02M$278.90M$147.54M-$63.54M-$66.94M$83.16M-$80.80M
Net Income$413.60M$316.89M$444.09M$281.59M$202.13M$402.71M$129.09M-$72.24M-$80.33M$62.97M-$103.02M
EPS (Diluted)n/a$2.56$3.43$2.10$1.44$2.74$0.91-$0.50-$0.56$0.45-$0.81
Total Assets$2.58B$2.53B$2.06B$1.73B$1.84B$1.10B$579.92M$565.87M$440.25M$519.95M$261.51M
Total Liabilities$2.43B$2.48B$1.70B$1.65B$1.67Bn/an/an/an/an/an/a
Long-Term Debtn/a$2.14B$1.51B$1.50B$1.51B$787.25M$0$383.05M$34.87M$125.14M$199.23M
Shareholders' Equity$143.54M$48.81M$363.82M$83.81M$169.80M$196.95M$151.05M$91.77M$248.89M$208.37M-$32.48M
Cash & Equivalents$163.14M$133.82M$115.85M$118.37M$234.19M$118.72M$147.70M$120.18M$57.94M$168.74M$66.76M
Operating Cash Flow$818.60M$651.56M$479.06M$388.57M$240.11M$299.44M$55.45M-$85.42M-$49.50M$134.05M-$50.38M
Capital Expenditures$12.37M$6.97M$10.70M$15.29M$4.81M$1.46M$2.50M$4.04M$4.66M$1.35M$3.14M
Free Cash Flow$806.22M$644.59M$468.37M$373.28M$235.30M$297.98M$52.95M-$89.46M-$54.16M$132.70M-$53.52M
Share Repurchases$371.61M$342.37M$250.00M$402.38M$200.00M$350.06M$150.12M$200.00M$0$0n/a
Shares Outstanding114.04M117.78M123.14M126.77M135.15M137.50M135.03M136.71M144.73M142.79M129.50M
Weighted Average Diluted Sharesn/a123.90M129.42M134.20M140.61M146.80M141.46M144.33M143.60M139.07M127.96M
EPS (Basic)n/a$2.64$3.50$2.13$1.48$2.86$0.95-$0.50-$0.56$0.46-$0.81

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView